prostate cancerprostatectomycancer recurrenceprostate-specific antigenIntroduction: Approximately 15-30% of men with localized prostate cancer will experience biochemical recurrence (BCR) after radical prostatectomy. Postoperative radiation therapy i... 查看全部>>Isharwal...
Postradiation therapy adenosquamous cell carcinoma of the prostate [ J ]. Prostate Cancer Prostatic Dis, 2000,3 (1) : 53-56.Helal M; Diaz J I; Tannenbaum A;.Postradiation therapy adenosquamous cell carcinoma of the prostate.Prostate Cancer Prostatic Dis.2000.53-56...
Purpose: Hypofractionated radiation therapy (RT) has promising long-term biochemical relapse-free survival (bRFS) with comparable toxicity for definitive treatment of prostate cancer. However, data reporting outcomes after adjuvant and s... Lewis,Stephen,L.,... - 《International Journal of Radiation...
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. et al.Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial...
Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (...
Treatment of locally advanced, poorly differentiated prostate cancer will be presented including a discussion of neo-adjuvant and adjuvant hormones, dose-escalation and neutron irradiation.;-- Strategies for post-radiation failures will be presented including data on cryotherapy, salvage prostatectomy and ...
Even though prostate cancer is the most common cancer among men, it is the most survivable with 91% of the men living 10 years post diagnosis. Because of its high survival rate, the quality of life post diagnosis and treatment is of great concern. Depending upon the treatment selected, post...
The trial's co-primary endpoint was the two-year change score from baseline in the bowel and urinary domains of the patient-reported Expanded Prostate Cancer Index Composite (EPIC) questionnaire. The COPORT treatment arm included 152 patients, and the HYPORT treatment arm included 144 patients. ...
Re: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate spec... However, short followup since biopsy precludes analysis of the predictive value of post-irradiation biopsy on long-term local and distant disease...
Indication bias is the major challenge in assessing treatment effectiveness in observational studies. We explored the potential advantages of using an inst... YF Kuo,JE Montie,VB Shahinian - 《Medical Care》 被引量: 34发表: 2012年 Value of Free Prostate-Specific Antigen (Hybritech Tandem-R) in...